市場調查報告書

心肌炎市場:洞察,流行病學,至2030年的預測

Myocarditis Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968104
出版日期 內容資訊 英文 131 Pages
商品交期: 最快1-2個工作天內
價格
心肌炎市場:洞察,流行病學,至2030年的預測 Myocarditis Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 2020年10月30日內容資訊: 英文 131 Pages
簡介

世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的心肌炎的市場規模,2017年是10億3,790萬美金。還有2017年的全球心肌炎總患者數估計17萬1,415人。

本報告提供世界主要7個國家(美國,歐洲5個國家(德國,西班牙,義大利,法國,及英國),日本)的心肌炎市場的相關調查,提供流行病學,市場規模和預測,成長要素及課題,各國市場分析,競爭情形,主要企業的產品等資訊。

目錄

第1章 主要洞察

第2章 市場概要

  • 2017年:心肌炎市場佔有率
  • 2030年:心肌炎市場佔有率

第3章 摘要整理

第4章 組織

第5章 疾病概要

  • 簡介
  • 分類
  • 症狀
  • 病因
  • COVID-19對心肌炎的影響
  • 診斷
    • 鑑別診斷

第6章 流行病學和患者數

  • 主要調查結果
  • 主要7個國家的總患者數

第7章 主要7個國家的流行病學

  • 前提條件與理論的根據
  • KOL的見解
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 治療和管理

第9章 未滿足需求

第10章 主要評估項目

  • CardiolRx-100:Cardiol Therapeutics
    • 藥物概要
    • 其他開發活動
    • 臨床開發
    • 產品簡介

第11章 市場分析主要7個國家

  • 主要調查結果
  • 的心肌炎市場規模主要7個國家

第12章 市場預測:主要7個國家

  • KOL的見解
  • 美國的市場規模
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第13章 市場成長要素

第14章 市場障礙

第15章 市場存取(點閱)

第16章 SWOT分析

第17章 案例研究

  • 戲劇症心肌炎:各案例研究檢討
  • COVID-19的戲劇症心肌炎的病例報告
  • 單純皰疹病毒的肝炎和併發的心肌炎範例

第18章 KOL的見解

第19章 參考文件

第20章 附錄

第21章 報告的調查手法

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

目錄
Product Code: DIMI1049

DelveInsight's 'Myocarditis- Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Myocarditis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.,

The Myocarditis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Myocarditis market Size from 2017 to 2030 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Myocarditis Disease Understanding and Treatment Algorithm

Myocarditis Overview

Myocarditis is a disease that causes inflammation of the myocardium. This inflammation enlarges and weakens the heart, creates scar tissue, and forces it to work harder to circulate blood and oxygen throughout the body. It is a condition that can have a vast clinical spectrum ranging from asymptomatic forms to fatal disease, but mostly it is present as new-onset heart failure with reduced left ventricular ejection fraction, with or without the viral syndrome. Myocarditis is an important cause of sudden cardiac death in young patients.

"Myocarditis" usually refers to "acute myocarditis" that must be considered in patients who present the recent onset of cardiac failure or arrhythmia. Often there is a history of an antecedent flu-like illness. Fulminant myocarditis is a distinct entity characterized by sudden onset of severe congestive heart failure or cardiogenic shock, usually following a flu-like illness.

Diagnosis and treatment of myocarditis can be challenging. A critical and integrated evaluation of clinical and instrumental noninvasive investigations (clinical history, echocardiography, cardiac magnetic resonance imaging) is fundamental for identifying cases of suspected myocarditis. However, the definite diagnosis of myocarditis is provided by histologic and immunohistochemical analysis of myocardial tissue samples obtained with an endomyocardial biopsy. Endomyocardial biopsy and cardiac magnetic resonance are the diagnostic modalities with the highest diagnostic yield.

Management is primarily supportive but also includes treating any identifiable cause. Depending on the etiology, treatment may be antiviral or immunosuppressive. Patients with heart failure should receive standard treatment, including beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and diuretics if needed. Immunosuppressive therapy has not shown clinical benefit, and therefore, it should not be used routinely except in patients with underlying systemic autoimmune or granulomatous inflammatory diseases. Symptomatic patients present with new-onset heart failure, malignant arrhythmias, conduction abnormalities, and sometimes hemodynamic instability require mechanical circulatory support. Although infrequent, such cases should be promptly recognized and aggressively treated.

Myocarditis Diagnosis and Treatment

It covers the details of conventional and current medical therapies, and diagnosis available in the Myocarditis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Myocarditis market report gives a thorough understanding of Myocarditis by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Myocarditis in the US, Europe, and Japan.

Myocarditis Epidemiology

The Persistent Myocarditis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myocarditis epidemiology segmented as the Total Incident Cases of Myocarditis, Gender-specific Cases of Myocarditis. The report includes the Incident scenario of Myocarditis in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Myocarditis Epidemiology

The epidemiology segment also provides the Myocarditis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total Incident population of Myocarditis associated in 7MM countries estimated to be was 171,415 in 2017.

Myocarditis Drug Chapters

The Myocarditis report's drug chapter segment encloses the detailed analysis of myocarditis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Myocarditis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Treatment of myocarditis includes general nonspecific measures to treat heart disease sequel, including heart failure (HF) therapy and treatment of arrhythmias according to current guidelines and scientific statements. Mechanical circulatory support and transplantation may remain a potential last resort for refractory heart failure patients despite optimum medical therapy.

Products detail in the report…

Myocarditis Emerging Drugs

CardiolRx-100 is an ultra-pure, pharmaceutical cannabidiol formulation for medical purposes being developed by Cardiol therapeutics. According to the current Good Manufacturing Practices (cGMP), it is manufactured under the most stringent quality standards. It is free from the psychotropic effects of THC, and who should not be exposed to THC. THC free (<5 ppm) is ideal for patients that are produced using controlled processes in a cGMP. The cGMP facility was inspected and approved by Health Canada and registered with the FDA as a pharmaceutical facility.

Based on the large body of experimental evidence of the anti-inflammatory activity of CBD in models of cardiovascular disease, Cardiol believes there is a significant opportunity to develop CardiolRx-100 as a potential breakthrough therapy for acute myocarditis that would be eligible for designation as an orphan drug. The company plans to commercialize CardiolRx in the market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America. Cardiol Therapeutics is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to inflammation sites in the heart associated with heart failure.

The company is planning to initiate a phase I study designed to measure pharmacokinetics of CardiolRx-100 in the second half of 2020. The study will also measure standard safety parameters at escalating doses to help select the optimal dosing levels for the planned international Phase II international trial in acute myocarditis latter half of 2020.

Products detail in the report…

Myocarditis Market Outlook

The Myocarditis market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Myocarditis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Myocarditis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Myocarditis market in 7MM is expected to change in the study period 2017-2030.

Ongoing research efforts in this area that may lead to novel treatment strategies directed toward pathway-specific targets including identifying genomic profiles that affect individual susceptibility to myocarditis or predict the likelihood of recovery.

Key Findings

This section includes a glimpse of the Myocarditis market in 7MM. Myocarditis's market size in the seven major markets was USD 1,037.9 million in 2017.

The United States Market Outlook

This section provides the total Myocarditis market size and market size by therapies in the United States.

The United States accounts for Myocarditis's highest market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Treatment of myocarditis remains largely supportive, and treating the symptoms affecting the heart often involves treatment for heart failure; depending on these symptoms, patients with heart failure should receive standard treatment including angiotensin-converting enzyme inhibitors (ACE) or angiotensin II receptor blockers (ARBs), diuretics, and the introduction of B-blockers such as bisoprolol, metoprolol succinate, or carvedilol once they are clinically stable. Digoxin should be used with caution and only in low doses in patients with viral myocarditis.

Although viral etiology is the most commonly identified cause, antiviral therapy's efficacy is unknown, and routine antiviral therapy is not recommended. Non-steroid anti-inflammatory agents should be avoided in the acute setting as they may impair the myocardium's healing.

ACE inhibitors relax and open up blood vessels, making pumping blood easier and straining the heart. They can control blood pressure and prevent the worsening of heart failure symptoms. ARBs are similar to ACE inhibitors; these relax the blood vessels and lower blood pressure. They may be used when ACE inhibitors are not suitable due to side effects.

Anticoagulants may be used to prevent blood clots. This may be used in people with atrial

fibrillation is the uneven flow of blood through the heart, which could cause clot formation.

Immunosuppressive therapy can be beneficial in patients with giant-cell myocarditis and sarcoidosis; however, its role in chronic, virus-negative myocarditis-although promising-requires further elucidation. The use of immunomodulatory and antiviral therapy remains investigational, mainly at this time. Large, randomized, controlled trials are needed to determine their role in the treatment of inflammatory heart.

Despite these treatment options, Myocarditis treatment is still problematic and may depend on etiologic diagnosis to distinguish infectious from the immune-mediated disease. Both pathogenic mechanisms may co-occur in individual patients

EU-5 Countries: Market Outlook

The total Myocarditis market size and market size by therapies in EU-5 are also mentioned.

Japan Market Outlook

The total Myocarditis market size and market size by therapies in Japan are also mentioned.

Myocarditis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Myocarditis market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Myocarditis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Myocarditis key players involved in developing targeted therapeutics.

Major players include Cardiol Therapeutics, Apitope, and Cantargia is expected to be launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Myocarditis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Myocarditis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Myocarditis market trend. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Myocarditis Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Myocarditis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Myocarditis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Myocarditis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Myocarditis market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Myocarditis market.

Report Highlights:

  • In the coming years, Myocarditis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Myocarditis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Myocarditis. The launch of emerging therapies will significantly impact the Myocarditis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Myocarditis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Myocarditis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Myocarditis Pipeline Analysis
  • Myocarditis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Myocarditis Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Myocarditis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Myocarditis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Myocarditis Market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Myocarditis total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Myocarditis market Size during the forecast period (2017-2030)?
  • At what CAGR, the Myocarditis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Myocarditis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Myocarditis market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of the Myocarditis?
  • What is the historical Myocarditis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of Myocarditis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Myocarditis?
  • Out of all 7MM countries, which country would have the highest Incident population of Myocarditis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Myocarditis?
  • What are the current treatment guidelines for treating Myocarditis in the USA, Europe, and Japan?
  • What are the Myocarditis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Myocarditis?
  • How many therapies are developed by each company for the treatment of Myocarditis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Myocarditis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocarditis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myocarditis and their status?
  • What are the key designations that have been granted for the emerging therapies for Myocarditis?
  • What are the global historical and forecasted market of Myocarditis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Myocarditis market.
  • To understand the future market competition in the Myocarditis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Myocarditis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Myocarditis market.
  • To understand the future market competition in the Myocarditis market.

Table of Contents

1. Key Insights

2. Myocarditis: Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Myocarditis in 2017
  • 2.2. Market Share (%) Distribution of Myocarditis in 2030

3. Executive Summary

4. Organizations

5. Disease Overview: Myocarditis

  • 5.1. Introduction
  • 5.2. Classification
  • 5.3. Signs and Symptoms
  • 5.4. Etiology
  • 5.5. Pathogenesis
  • 5.6. Impact of Covid-19 on Myocarditis
  • 5.7. Diagnosis
    • 5.7.1. Differential Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Incident Cases of Myocarditis

7. 7MM Epidemiology of Myocarditis

  • 7.1. Assumptions and Rationale
  • 7.2. Epidemiology KOL views
  • 7.3. United States
    • 7.3.1. Total Incident Cases of Myocarditis in the United States
    • 7.3.2. Gender-specific cases of Myocarditis in the US
  • 7.4. Germany
    • 7.4.1. Total incident Cases of Myocarditis in Germany
    • 7.4.2. Gender-specific cases of Myocarditis in Germany
  • 7.5. France
    • 7.5.1. Total incident Cases of Myocarditis in France
    • 7.5.2. Gender-specific cases of Myocarditis in France
  • 7.6. Italy
    • 7.6.1. Total incident Cases of Myocarditis in Italy
    • 7.6.2. Gender-specific cases of Myocarditis in Italy
  • 7.7. Spain
    • 7.7.1. Total incident Cases of Myocarditis in Spain
    • 7.7.2. Gender-specific cases of Myocarditis in Spain
  • 7.8. United Kingdom
    • 7.8.1. Total incident Cases of Myocarditis in United kingdom
    • 7.8.2. Gender-specific cases of Myocarditis in the UK
  • 7.9. Japan
    • 7.9.1. Total incident Cases of Myocarditis in Japan
    • 7.9.2. Gender-specific cases of Myocarditis in Japan

8. Treatment and Management

9. Unmet Needs

10. Key Cross Competition

  • 10.1. CardiolRx-100: Cardiol Therapeutics
    • 10.1.1. Drug Description
    • 10.1.2. Other Developmental Activities
    • 10.1.3. Clinical Development
    • 10.1.4. Product Profile

11. Myocarditis: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Myocarditis in 7MM

12. Market Outlook: 7MM

  • 12.1. Market KOL views
  • 12.2. The United States Market Size
    • 12.2.1. Total market size of Myocarditis in the United States
    • 12.2.2. Market size of Myocarditis by Therapies in the US
  • 12.3. Germany Market Size
    • 12.3.1. Total market size of Myocarditis in Germany
    • 12.3.2. Market size of Myocarditis by Therapies in Germany
  • 12.4. France Market Size
    • 12.4.1. Total market size of Myocarditis in France
    • 12.4.2. The market size of Myocarditis by Therapies in France
  • 12.5. Italy Market Size
    • 12.5.1. Total market size of Myocarditis in Italy
    • 12.5.2. Market size of Myocarditis by Therapies in Italy
  • 12.6. Spain Market Size
    • 12.6.1. Total market size of Myocarditis in Spain
    • 12.6.2. Market size of Myocarditis by Therapies in Spain
  • 12.7. The UK Market Size
    • 12.7.1. Total market size of Myocarditis in the UK
    • 12.7.2. Market size of Myocarditis by Therapies in The UK
  • 12.8. Japan Market Size
    • 12.8.1. Total market size of Myocarditis in Japan
    • 12.8.2. Market size of Myocarditis by Therapies in Japan

13. Market Drivers

14. Market Barriers

15. Market Access

16. SWOT Analysis

17. Case Studies

  • 17.1. Fulminant Myocarditis-Review with Case Studies
  • 17.2. A Case Report of COVID-19 Fulminant Myocarditis
  • 17.3. A Case of Myocarditis Combined with Hepatitis Caused by Herpes Simplex Virus

18. KOL views

19. Bibliography

20. Appendix

21. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: Etiological forms of Myocarditis
  • Table 2: Diagnostic criteria for clinically suspected Myocarditis
  • Table 3: Classification of Myocarditis by Endomyocardial biopsy using the Dallas criteria
  • Table 4: Typical echocardiographic features of classic vs. fulminant Myocarditis
  • Table 5: Diagnosis of Myocarditis by cMRI (original and revised Lake Louise Criteria)
  • Table 6: 3-Tier classification for the diagnosis of Myocarditis
  • Table 7: Diagnostic Guidelines for Eosinophilic Myocarditis
  • Table 8: Total Incident Cases of Myocarditis in USD Million (2017-2030)
  • Table 9: Total Incident Cases of Myocarditis in the US (2017-2030)
  • Table 10: Gender-specific cases of Myocarditis in the US (2017-2030)
  • Table 11: Total Incident Cases of Myocarditis in Germany (2017-2030)
  • Table 12: Gender-specific cases of Myocarditis in Germany (2017-2030)
  • Table 13: Total Incident Cases of Myocarditis in France (2017-2030)
  • Table 14: Gender-specific cases of Myocarditis in France (2017-2030)
  • Table 15: Total Incident Cases of Myocarditis in Italy (2017-2030)
  • Table 16: Gender-specific cases of Myocarditis in Italy (2017-2030)
  • Table 17: Total Incident Cases of Myocarditis in Spain (2017-2030)
  • Table 18: Gender-specific cases of Myocarditis in Spain (2017-2030)
  • Table 19: Total Incident Cases of Myocarditis in the UK (2017-2030)
  • Table 20: Gender-specific cases of Myocarditis in the UK (2017-2030)
  • Table 21: Total Incident Cases of Myocarditis in Japan (2017-2030)
  • Table 22: Gender-specific cases of Myocarditis in Japan (2017-2030)
  • Table 23: Key cross competition
  • Table 24: Market Size of Myocarditis in 7MM in USD Million (2017-2030)
  • Table 25: Total Market Size of Myocarditis in the US in USD Million (2017-2030)
  • Table 26: The US Market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 27: Total Market Size of Myocarditis in Germany in USD Million (2017-2030)
  • Table 28: Germany Market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 29: Total Market Size of Myocarditis in France in USD Million (2017-2030)
  • Table 30: France Market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 31: Total Market Size of Myocarditis in Italy in USD Million (2017-2030)
  • Table 32: Italy Market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 33: Total Market Size of Myocarditis in Spain in USD Million (2017-2030)
  • Table 34: Spain Market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 35: Total Market Size of Myocarditis in the UK in USD Million (2017-2030)
  • Table 36: The UK market Size of Myocarditis by Therapies, in USD Million (2017-2030)
  • Table 37: Total Market Size of Myocarditis in Japan in USD Million (2017-2030)
  • Table 38:Japan market Size of Myocarditis by Therapies, in USD Million (2017-2030)

List of Figures

  • Figure 1: Histology Based Classification
  • Figure 2: Clinicopathological based classification
  • Figure 3: Etiology based classification
  • Figure 4: Clinical Presentation associated with Myocarditis
  • Figure 5: Etiology Associated with Myocarditis
  • Figure 6: Pathogenic mechanisms involved in Myocarditis and progression to dilated cardiomyopathy
  • Figure 7: Hypothesis of the Development of Noninfectious Myocarditis
  • Figure 8: Total Incident Cases of Myocarditis in 7MM (2017-2030)
  • Figure 9: Total Incident Cases of Myocarditis in the US (2017-2030)
  • Figure 10: Gender-specific cases of Myocarditis in the US (2017-2030)
  • Figure 11: Total Incident Cases of Myocarditis in Germany (2017-2030)
  • Figure 12: Gender-specific cases of Myocarditis in Germany (2017-2030)
  • Figure 13: Total Incident Cases of Myocarditis in France (2017-2030)
  • Figure 14: Gender-specific cases of Myocarditis in France (2017-2030)
  • Figure 15: Total Incident Cases of Myocarditis in Italy (2017-2030)
  • Figure 16: Gender-specific cases of Myocarditis in Italy (2017-2030)
  • Figure 17: Total Incident Cases of Myocarditis in Spain (2017-2030)
  • Figure 18: Gender-specific cases of Myocarditis in Spain (2017-2030)
  • Figure 19: Total Incident Cases of Myocarditis in the UK (2017-2030)
  • Figure 20: Gender-specific cases of Myocarditis in the UK (2017-2030)
  • Figure 21: Total Incident Cases of Myocarditis in Japan (2017-2030)
  • Figure 22: Gender-specific cases of Myocarditis in Japan (2017-2030)
  • Figure 23: Unmet Needs
  • Figure 24: Market Size of Myocarditis in USD Million (2017-2030)
  • Figure 25: Total Market Size of Myocarditis in the US, USD Millions (2017-2030)
  • Figure 26: The US Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 27: Total Market Size of Myocarditis in Germany, USD Millions (2017-2030)
  • Figure 28: Germany Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 29: Total Market Size of Myocarditis in France, USD Millions (2017-2030)
  • Figure 30: France Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 31: Total Market Size of Myocarditis in Italy, USD Millions (2017-2030)
  • Figure 32: Italy Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 33: Total Market Size of Myocarditis in Spain, USD Millions (2017-2030)
  • Figure 34: Spain Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 35: Total Market Size of Myocarditis in the UK, USD Millions (2017-2030)
  • Figure 36: The UK Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 37: Total Market Size of Myocarditis in Japan, USD Millions (2017-2030)
  • Figure 38: Japan Market Size of Myocarditis by Therapies USD Millions (2017-2030)
  • Figure 39: Market Drivers
  • Figure 40:Market Barriers